why choose us

First received: June 14, 2023

Clinical Trial: Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Neovascular Age-related Macular Degeneration

Study Type: INTERVENTIONAL


Official Title: A Multi-center, Open-Label, Phase 1, Single- and Multiple Ascending Dose Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (nAMD).

Brief Summary: This is a Phase 1 study, first-in-human (FIH), open label study to evaluate the safety, tolerability and identify the maximum tolerated dose (MTD) of PMC-403 and determine the recommended phase 2 dose (RP2D).

Read more